Neu H C
Pharmacotherapy. 1985 Jan-Feb;5(1):1-10. doi: 10.1002/j.1875-9114.1985.tb04448.x.
Amdinocillin is a novel penicillin whose antibacterial activity is derived from its ability to bind specifically and avidly to Penicillin Binding Protein-2 (PBP 2). Other beta-lactams bind almost exclusively to PBPs 1 and 3. This unique feature has prompted many investigators to predict that amdinocillin would aggressively synergize with other antimicrobials, particularly other beta-lactams. Certain features of these predictions have been realized. Amdinocillin is active alone against many gram-negative organisms. Pseudomonas and non-fermenting gram-negative bacteria, however, are usually resistant. Amdinocillin, in combination with many beta-lactams, exhibits marked synergy against many enterobacteriaceae. No such synergy can be demonstrated for gram-positive organisms or pseudomonas species. Amdinocillin is not beta-lactamase stable. Organisms which produce high levels of plasma-mediated beta-lactamase are resistant to the drug. Amdinocillin is widely distributed to most tissues of the body. It is removed by renal tubular secretion which results in prodigious levels of the drug in the urine. Co-administration of probenecid results in markedly elevated plasma levels of amdinocillin and delays its excretion. Amdinocillin has a plasma half-life of about one hour in patients with grossly normal renal function. Its half-life increases to 3 to 6 hours in anephric patients. The spectrum of adverse reactions observed with amdinocillin is similar to that of other penicillins. Amdinocillin, as a single agent, is effective in the treatment of urinary tract infections caused by susceptible strains of E. coli and klebsiella and enterobacter species. When amdinocillin is used in concert with other antimicrobials, synergy can frequently be demonstrated but it is essentially limited to gram-negative aerobic organisms. At present, insufficient data are available to precisely profile the utility of amdinocillin, either alone or in combination, in the treatment of systemic infections.
氨比西林是一种新型青霉素,其抗菌活性源于它能特异性且紧密地结合青霉素结合蛋白-2(PBP 2)。其他β-内酰胺类药物几乎只与PBP 1和PBP 3结合。这一独特特性促使许多研究人员预测氨比西林会与其他抗菌药物,尤其是其他β-内酰胺类药物产生强烈协同作用。这些预测的某些方面已经得到证实。氨比西林单独对许多革兰氏阴性菌有活性。然而,铜绿假单胞菌和非发酵革兰氏阴性菌通常具有耐药性。氨比西林与许多β-内酰胺类药物联合使用时,对许多肠杆菌科细菌表现出显著的协同作用。对于革兰氏阳性菌或铜绿假单胞菌属,未显示出这种协同作用。氨比西林对β-内酰胺酶不稳定。产生高水平血浆介导β-内酰胺酶的细菌对该药物耐药。氨比西林广泛分布于身体的大多数组织。它通过肾小管分泌排出,这导致尿液中药物浓度极高。丙磺舒联合使用会使氨比西林的血浆水平显著升高并延迟其排泄。在肾功能大致正常的患者中,氨比西林的血浆半衰期约为1小时。在无肾患者中,其半衰期延长至3至6小时。氨比西林观察到的不良反应谱与其他青霉素类相似。氨比西林作为单一药物,可有效治疗由大肠埃希菌、克雷伯菌和肠杆菌属敏感菌株引起的尿路感染。当氨比西林与其他抗菌药物联合使用时,常常能显示出协同作用,但基本上仅限于革兰氏阴性需氧菌。目前,尚无足够数据精确描述氨比西林单独或联合使用在治疗全身感染中的效用。